Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

被引：106

作者：

Popat, Rakesh ^{[1
]}

Oakervee, Heather E. ^{[1
]}

Hallam, Simon ^{[1
]}

Curry, Nicola ^{[1
]}

Odeh, Liz ^{[1
]}

Foot, Nicola ^{[1
]}

Esseltine, Dixie-Lee ^{[2
]}

Drake, Mary ^{[3
]}

Morris, Curly ^{[3
]}

Cavenagh, Jamie D. ^{[1
]}

机构：

[1] St Bartholomews Hosp, Dept Haematol, London EC1A 7BE, England

[2] Millennium Pharmaceut Inc, Cambridge, MA USA

[3] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷 / 04期

关键词：

multiple myeloma; bortezomib; doxorubicin; dexamethasone; induction;

D O I：

10.1111/j.1365-2141.2008.06997.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly active as front-line induction in MM.

引用

页码：512 / 516

页数：5

共 13 条

[1] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[2]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[3] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[4] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[5]

Harousseau JL, 2006, HAEMATOLOGICA, V91, P1498

[6]

Hideshima T, 2001, CANCER RES, V61, P3071

[7]

Jagannath S, 2006, BLOOD, V108, p238A

[8]

Jakubowiak A, 2007, HAEMATOL-HEMATOL J, V92, P180

[9]

Ma MH, 2003, CLIN CANCER RES, V9, P1136

[10] Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European group for blood and marrow transplantation registry study [J].

Morris, C ;

Iacobelli, S ;

Brand, R ;

Bjorkstrand, B ;

Drake, M ;

Niederwieser, D ;

Gahrton, G .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1674-1681

← 1 2 →